RVO
HomeMarketplace

ServiceUpdated on 1 September 2025

In Silico Solutions to De-risk Drug Development and Empower Precision Medicine

Rositsa Jordanova

CEO and founder at Protyon

Groningen, Netherlands

About

Our service can:

- Help de-risk development pipelines by assessing the impact of novel mutations (e.g., kinase activation), supporting patient selection for targeted therapies and reducing unsuccessful treatments;
- Evaluate drug efficacy by analyzing both simple and complex mutations;
- Assist with cohort selection by refining patient inclusion criteria for clinical trials, increasing trial success rates.

Our services are ideally suited for advanced targeted therapies, with current expertise focused on tyrosine kinase inhibitors (TKIs).

Type

  • Development
  • Consulting

Applies to

  • Innovative therapies - Precision medicine
  • Innovative human-based test models - In silico human models
  • Development stages and support fuctions - Pre-clinical research and development
  • Development stages and support fuctions - Clinical research and development
  • Development stages and support fuctions - Contract research (CRO / CRMO)

Organisation

Protyon

Company

Groningen, Netherlands

Similar opportunities